EICHORPublic-registry trials using Cobitolimod 250 mg that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
Cobitolimod 250 mg appears in 1 registered trial Eichor's radar has found, sponsored by InDex Pharmaceuticals, the most recent registered as Phase 3, with a planned enrollment of 171. Registered timeline: 2021–2023. The registry holds 1,879 registered studies for Ulcerative Colitis.
| Trial | Sponsor | Condition | Phase | Sites |
| The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis | InDex Pharmaceuticals | Ulcerative Colitis | PHASE3 | 203 |
| Status | Terminated · planned start 2021-11 |
| Primary completion | 2023-12 |
| Enrollment target | 171 participants |
| Design | Randomized · Parallel · Phase 3 · 3 arms |
| Who it enrolls | All sexes · 18 Years and older — full criteria are on the study record |
| Locations | 203 listed in Australia, Austria, Belgium, Bosnia and Herzegovina |
All fields verbatim from the ClinicalTrials.gov record for NCT04985968.
| First registered study | June 2017 — NCT03178669 (InDex Pharmaceuticals) |
| Registered studies matching this name | 2 all-time · 0 currently recruiting |
Source: ClinicalTrials.gov, the public trial registry.
The public registry holds 1,879 registered studies for Ulcerative Colitis. Compounds appearing across the 200 most recently updated registry entries:
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Trialed alongside
Other Ulcerative Colitis drugs
← Eichor home · All tracked trials · Ulcerative Colitis studies · Weekly briefs
